Mcguire Dvamc

Richmond, Virginia 23249

0 studies enrolling now · 35 studies all time

What they study most

Carcinoma, Hepatocellular, Colitis, Ulcerative, Crohn's Disease, Fistulizing Crohn's Disease, Gastrointestinal Disease, Hepatic Cirrhosis, Hepatic Fibrosis, Hepatitis B, Hepatitis C, Hepatitis C Virus, Hepatitis C, Chronic, Hepato Cellular Carcinoma (HCC)

Studies at this site

• Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis — Running, not enrolling
• Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease — Stopped early
• Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) — Stopped early
• Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis — Stopped early
• A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin — Completed
• Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis — Completed
• Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis — Completed
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease — Completed
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) — Completed
• Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) — Completed
• A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis — Completed
• Long-Term Safety Of PF-00547659 In Ulcerative Colitis — Completed
• Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease — Completed
• Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008 — Completed
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis — Completed
• Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) — Completed
• A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV — Completed
• Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial — Completed
• Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment — Completed
• Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease — Stopped early
• Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) — Completed
• A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension — Completed
• First Line Hepato Cellular Carcinoma (HCC) — Completed
• A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis — Completed
• A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. — Completed
• BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C — Completed
• Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) — Completed
• A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy — Completed
• AST-120 Used to Treat Mild Hepatic Encephalopathy — Completed
• Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation — Completed
• Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV — Completed
• Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis — Completed
• Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin — Completed
• CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission — Completed
• Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer — Stopped early